Celiac disease and transglutaminase 2: a model for posttranslational modification of antigens and HLA association in the pathogenesis of autoimmune disorders

Trynka, 2010, A genetic perspective on coeliac disease, Trends Mol Med, 16, 537, 10.1016/j.molmed.2010.09.003 Karell, 2003, HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease, Hum Immunol, 64, 469, 10.1016/S0198-8859(03)00027-2 Dubois, 2010, Multiple common variants for celiac disease influencing immune gene expression, Nat Genet, 42, 295, 10.1038/ng.543 Smyth, 2008, Shared and distinct genetic variants in type 1 diabetes and celiac disease, N Engl J Med, 359, 2767, 10.1056/NEJMoa0807917 Lorand, 2003, Transglutaminases: crosslinking enzymes with pleiotropic functions, Nat Rev Mol Cell Biol, 4, 140, 10.1038/nrm1014 Liu, 2002, Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity, Proc Natl Acad Sci USA, 99, 2743, 10.1073/pnas.042454899 Pinkas, 2007, Transglutaminase 2 undergoes a large conformational change upon activation, PLoS Biol, 5, e327, 10.1371/journal.pbio.0050327 Siegel, 2008, Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury, PLoS One, 3, e1861, 10.1371/journal.pone.0001861 Stamnaes, 2010, Redox regulation of transglutaminase 2 activity, J Biol Chem, 285, 25402, 10.1074/jbc.M109.097162 Castellani, 2008, The thiol redox state of lymphoid organs is modified by immunization: role of different immune cell populations, Eur J Immunol, 38, 2419, 10.1002/eji.200838439 Tye-Din, 2010, Comprehensive, quantitative mapping of T cell epitopes in gluten in celiac disease, Sci Transl Med, 2, 41ra51, 10.1126/scitranslmed.3001012 Hovhannisyan, 2008, The role of HLA-DQ8 β57 polymorphism in the anti-gluten T-cell response in coeliac disease, Nature, 456, 534, 10.1038/nature07524 Arentz-Hansen, 2002, Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues, Gastroenterology, 123, 803, 10.1053/gast.2002.35381 Shan, 2002, Structural basis for gluten intolerance in celiac sprue, Science, 297, 2275, 10.1126/science.1074129 Vartdal, 1996, The peptide binding motif of the disease associated HLA-DQ(α1*0501, β1*0201) molecule, Eur J Immunol, 26, 2764, 10.1002/eji.1830261132 van de Wal, 1996, Peptide binding characteristics of the coeliac disease-associated DQ(α1*0501, β1*0201) molecule, Immunogenetics, 44, 246, 10.1007/BF02602553 Kim, 2004, Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease, Proc Natl Acad Sci USA, 101, 4175, 10.1073/pnas.0306885101 Kwok, 1996, Allele-specific motifs characterize HLA-DQ interactions with a diabetes-associated peptide derived from glutamic acid decarboxylase, J Immunol, 156, 2171, 10.4049/jimmunol.156.6.2171 Henderson, 2007, A structural and immunological basis for the role of human leukocyte antigen DQ8 in celiac disease, Immunity, 27, 23, 10.1016/j.immuni.2007.05.015 Tollefsen, 2006, HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease, J Clin Invest, 116, 2226, 10.1172/JCI27620 Fallang, 2009, Differences in the risk of celiac disease associated with HLA-DQ2.5 or HLA-DQ2.2 are related to sustained gluten antigen presentation, Nat Immunol, 10, 1096, 10.1038/ni.1780 van de Wal, 1997, Unique peptide binding characteristics of the disease-associated DQ(α1*0501, β1*0201) vs the non-disease-associated DQ(α1*0201, β1*0202) molecule, Immunogenetics, 46, 484, 10.1007/s002510050309 Johansen, 1996, Both alpha and beta chain polymorphisms determine the specificity of the disease-associated HLA-DQ2 molecules, with beta chain residues being most influential, Immunogenetics, 45, 142, 10.1007/s002510050182 Vader, 2003, The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses, Proc Natl Acad Sci USA, 100, 12390, 10.1073/pnas.2135229100 Qiao, 2005, Refining the rules of gliadin T cell epitope binding to the disease-associated DQ2 molecule in celiac disease: importance of proline spacing and glutamine deamidation, J Immunol, 175, 254, 10.4049/jimmunol.175.1.254 Vader, 2002, Specificity of tissue transglutaminase explains cereal toxicity in celiac disease, J Exp Med, 195, 643, 10.1084/jem.20012028 Fleckenstein, 2002, Gliadin T cell epitope selection by tissue transglutaminase in celiac disease. Role of enzyme specificity and pH influence on the transamidation versus deamidation process, J Biol Chem, 277, 34109, 10.1074/jbc.M204521200 Dorum, 2009, A quantitative analysis of transglutaminase 2-mediated deamidation of gluten peptides: implications for the T-cell response in celiac disease, J Proteome Res, 8, 1748, 10.1021/pr800960n Dorum, 2010, The preferred substrates for transglutaminase 2 in a complex wheat gluten digest are peptide fragments harboring celiac disease T-cell epitopes, PLoS One, 5, e14056, 10.1371/journal.pone.0014056 Xia, 2005, Equilibrium and kinetic analysis of the unusual binding behavior of a highly immunogenic gluten peptide to HLA-DQ2, Biochemistry, 44, 4442, 10.1021/bi047747c Qiao SW, Ráki M, Gunnarsen KS, Løset GÅ, Lundin KE, Sandlie I, Sollid LM: Post-translational modification of gluten shapes T-cell receptor usage in celiac disease. J Immunol 2011, doi:10.4049/jimmunol.1101526 Doyle, 2001, Post-translational protein modifications in antigen recognition and autoimmunity, Trends Immunol, 22, 443, 10.1016/S1471-4906(01)01976-7 Petersen, 2009, Post-translationally modified T cell epitopes: immune recognition and immunotherapy, J Mol Med (Berl), 87, 1045, 10.1007/s00109-009-0526-4 Baker, 2002, Restricted islet-cell reactive T cell repertoire of early pancreatic islet infiltrates in NOD mice, Proc Natl Acad Sci USA, 99, 9374, 10.1073/pnas.142284899 Stadinski, 2010, Chromogranin A is an autoantigen in type 1 diabetes, Nat Immunol, 11, 225, 10.1038/ni.1844 Osman, 2000, B cell epitopes of gliadin, Clin Exp Immunol, 121, 248, 10.1046/j.1365-2249.2000.01312.x Girbal-Neuhauser, 1999, The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues, J Immunol, 162, 585, 10.4049/jimmunol.162.1.585 Schellekens, 1998, Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies, J Clin Invest, 101, 273, 10.1172/JCI1316 Molberg, 1998, Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells, Nat Med, 4, 713, 10.1038/nm0698-713 van de Wal, 1998, Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity, J Immunol, 161, 1585, 10.4049/jimmunol.161.4.1585 Vossenaar, 2003, PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease, Bioessays, 25, 1106, 10.1002/bies.10357 Dieterich, 1997, Identification of tissue transglutaminase as the autoantigen of celiac disease, Nat Med, 3, 797, 10.1038/nm0797-797 Zhao, 2008, Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis, J Rheumatol, 35, 969 Halvorsen, 2008, Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity, Ann Rheum Dis, 67, 414, 10.1136/ard.2007.080267 Dessen, 1997, X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II, Immunity, 7, 473, 10.1016/S1074-7613(00)80369-6 Hill, 2003, Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule, J Immunol, 171, 538, 10.4049/jimmunol.171.2.538